Attorneys: FDA Could Require Opioid Take-Back Programs As Part Of REMS Requirements

As FDA rethinks some of its Risk Evaluation and Mitigation Strategies (REMS) requirements on opioid manufacturers, some attorneys, including a former FDA chief counsel, agree the agency could consider including a take-back program as part of the restrictions, despite what's seen as inevitable pushback from industry. Industry has previously sued in attempts to block mandated take back programs, and industry groups appeared opposed to the opioid take-back idea when asked by Inside Health Policy . While declaring the opioid epidemic...